Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy

Hepatobiliary and Pancreatic Diseases International

Volumn 11, Issue 5, 2012, Pages 499-506

  Park, Yongjung ^a   Park, Jun Yong ^a   Han, Kwang Hyub ^a   Kim, Hyon Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Cytokine; Hepatitis B virus; Peginterferon; Protein chip array

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PEGINTERFERON ALPHA2A; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

EID: 84867773992     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(12)60214-8     Document Type: Article

References (25)

1. Zhang JY, Zou ZS, Huang A, Zhang Z, Fu JL, Xu XS, et al. Hyper-activated pro-inflammatory CD16 monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B. PLoS One 2011;6:e17484.
2. Zhang Z, Zhang S, Zou Z, Shi J, Zhao J, Fan R, et al. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 2011;53:73-85.
3. Ito H, Ando K, Ishikawa T, Saito K, Takemura M, Imawari M, et al. Role of TNF-alpha produced by nonantigen-specific cells in a fulminant hepatitis mouse model. J Immunol 2009; 182:391-397.
4. Wells RG. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol 2005;39: S158-161.
5. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115: 209-218.
6. Rossmanith W, Schulte-Hermann R. Biology of transforming growth factor beta in hepatocarcinogenesis. Microsc Res Tech 2001;52:430-436.
7. Okumoto K, Hattori E, Tamura K, Kiso S, Watanabe H, Saito K, et al. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 2004;24:21-28.
8. Lee WC, Chiang YJ, Wang HC, Wang MR, Lia SR, Chen MF. Functional impairment of dendritic cells caused by murine hepatocellular carcinoma. J Clin Immunol 2004;24:145-154.
9. Hosel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009;50:1773-1782.
10. Kao JT, Lai HC, Tsai SM, Lin PC, Chuang PH, Yu CJ, et al. Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naive hepatitis B infection patients. Liver Int 2012;32:928-936.
11. Ayada M, Ishikawa T, Okumura A, Tanabe J, Ito H, Ohashi T, et al. Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection. Hepatol Res 2006;34:214-221.
12. Akpolat N, Yahsi S, Godekmerdan A, Demirbag K, Yalniz M. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol 2005;11:3260-3263.
13. Tan AT, Koh S, Goh W, Zhe HY, Gehring AJ, Lim SG, et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol 2010; 52:330-339.
14. Park Y, Han KH, Kim HS. Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy. J Clin Lab Anal 2011;25:414-421.
15. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
16. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588.
17. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791.
18. Fukai K, Zhang KY, Imazeki F, Kurihara T, Mikata R, Yokosuka O. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase. J Viral Hepat 2007;14:661-666.
19. Ajuebor MN, Hogaboam CM, Le T, Swain MG. C-C chemokine ligand 2/monocyte chemoattractant protein-1 directly inhibits NKT cell IL-4 production and is hepatoprotective in T cell-mediated hepatitis in the mouse. J Immunol 2003;170:5252-5259.
20. Panasiuk A, Prokopowicz D, Panasiuk B. Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C. World J Gastroenterol 2004;10:3639-3642.
21. Park BL, Kim YJ, Cheong HS, Kim LH, Choi YH, Lee HS, et al. Association of common promoter polymorphisms of MCP1 with hepatitis B virus clearance. Exp Mol Med 2006; 38:694-702.
22. Marsillach J, Bertran N, Camps J, Ferre N, Riu F, Tous M, et al. The role of circulating monocyte chemoattractant protein-1 as a marker of hepatic inflammation in patients with chronic liver disease. Clin Biochem 2005;38:1138-1140.
23. Kuo TM, Hu CP, Chen YL, Hong MH, Jeng KS, Liang CC, et al. HBV replication is significantly reduced by IL-6. J Biomed Sci 2009;16:41.
24. Pan CJ, Wu HL, Kuo SF, Kao JH, Tseng TC, Liu CH, et al. Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. Hepatol Int 2011;6:591-597.
25. Barreiros AP, Sprinzl M, Rosset S, Hohler T, Otto G, Theobald M, et al. EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix interactions in primary human hepatocytes. Int J Cancer 2009;124:120-129.